Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/116128
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
Author: Nation, R.
Li, J.
Cars, O.
Couet, W.
Dudley, M.
Kaye, K.
Mouton, J.
Paterson, D.
Tam, V.
Theuretzbacher, U.
Tsuji, B.
Turnidge, J.
Citation: Lancet Infectious Diseases, 2015; 15(2):225-234
Publisher: Elsevier
Issue Date: 2015
ISSN: 1473-3099
1474-4457
Statement of
Responsibility: 
Roger L Nation, Jian Li, Otto Cars, William Couet, Michael N Dudley, Keith S Kaye, Johan W Mouton, David L Paterson, Vincent H Tam, Ursula Theuretzbacher, Brian T Tsuji, John D Turnidge
Abstract: In the face of diminishing therapeutic options for the treatment of infections caused by multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and polymyxin B. These antibiotics became available clinically in the 1950s, when understanding of antimicrobial pharmacology and regulatory requirements for approval of drugs was substantially less than today. At the 1st International Conference on Polymyxins in Prato, Italy, 2013, participants discussed a set of key objectives that were developed to explore the factors affecting the safe and effective use of polymyxins, identify the gaps in knowledge, and set priorities for future research. Participants identified several factors that affect the optimum use of polymyxins, including: confusion caused by several different conventions used to describe doses of colistin; an absence of appropriate pharmacopoeial standards for polymyxins; outdated and diverse product information; and uncertainties about susceptibility testing and breakpoints. High-priority areas for research included: better definition of the effectiveness of polymyxin-based combination therapy compared with monotherapy via well designed, randomised controlled trials; examination of the relative merits of colistin versus polymyxin B for various types of infection; investigation of pharmacokinetics in special patient populations; and definition of the role of nebulised polymyxins alone or in combination with intravenous polymyxins for the treatment of pneumonia. The key areas identified provide a roadmap for action regarding the continued use of polymyxins, and are intended to help with the effective and safe use of these important, last-line antibiotics.
Keywords: Gram-negative bacterial infections; colistin; polymyxin B
Rights: © 2015 Elsevier Ltd. All rights reserved.
DOI: 10.1016/S1473-3099(14)70850-3
Appears in Collections:Aurora harvest 3
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.